Epoetin Alfa

Epoetin alfa (Epogen, Procrit) is a real, FDA-approved recombinant erythropoietin — one of the first blockbuster biotech drugs ever approved, in 1989 — carrying a real, significant 2007 boxed warning after multiple trials found that dosing to normal or near-normal hemoglobin levels increased death, cardiovascular events, and tumor progression rather than helping.

A landmark early biotech drug

Epoetin alfa is recombinant human erythropoietin (EPO), the hormone that stimulates red blood cell production in bone marrow — the same 165-amino-acid sequence as the hormone your kidneys naturally produce. The FDA approved it on 1 June 1989 for anemia associated with chronic kidney failure, one of the first blockbuster biotech drugs of the recombinant-DNA era; indications later expanded to zidovudine-associated anemia in HIV and chemotherapy-induced anemia.

The safety controversy — real, and significant

This is the central, honest story of this drug class. The Normal Hematocrit Trial (Besarab et al., N Engl J Med 1998, PMID 9718377) randomized 1,233 hemodialysis patients with heart disease to a hematocrit target of 42% versus 30% — and found normalizing hematocrit was not beneficial, with a trend toward more nonfatal MI/death in the higher-target group, stopping the trial early. Years later, CHOIR (Singh et al., N Engl J Med 2006, PMID 17108343) randomized 1,432 CKD patients not yet on dialysis to a hemoglobin target of 13.5 versus 11.3 g/dL, finding a significantly increased risk of death, MI, heart-failure hospitalization, or stroke in the higher-target group (HR 1.34). A companion trial published the same week, CREATE (Drüeke et al., N Engl J Med 2006, PMID 17108342), reached a similarly cautionary conclusion. In cancer patients specifically, the BEST trial (Leyland-Jones et al., J Clin Oncol 2005, PMID 16087945) found worse 12-month survival with epoetin alfa targeting a high hemoglobin range in metastatic breast cancer (70% vs. 76%, p=0.01), and a separate trial in head-and-neck cancer patients on radiotherapy (Henke et al., Lancet 2003) found worse tumor control and survival with an erythropoietin-class drug used to correct anemia during treatment — directly raising the concern that these drugs could stimulate tumor growth through erythropoietin receptors on cancer cells themselves.

The 2007 boxed warning

Based on this accumulated evidence, the FDA required a class-wide boxed warning across all erythropoiesis-stimulating agents (Epogen, Procrit, and darbepoetin alfa) — an initial black-box addition on 12 March 2007, with further revisions and restrictions added on 8 November 2007. The warning: these drugs increase the risk of death, serious cardiovascular events, and tumor progression/recurrence when dosed to target a hemoglobin above 12 g/dL, and the label now instructs using the lowest dose needed to avoid a transfusion — never to normalize hemoglobin.

Current status

Still marketed — Epogen (Amgen, dialysis-focused distribution) and Procrit (Janssen). The first biosimilar, Retacrit (epoetin alfa-epbx, Pfizer/Hospira), was FDA-approved 15 May 2018.